Different cellular effects of four anti-inflammatory eye drops on human corneal epithelial cells: independent in active components

Mingli Qu, Yao Wang, Lingling Yang, Qingjun Zhou

State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong Academy of medical Sciences, Qingdao, China

Purpose: To evaluate and compare the cellular effects of four commercially available anti-inflammatory eye drops and their active components on human corneal epithelial cells (HCECs) in vitro.

Methods: The cellular effects of four eye drops (Bromfenac Sodium Hydrate Eye Drops, Pranoprofen Eye Drops, Diclofenac Sodium Eye Drops, and Tobramycin & Dex Eye Drops) and their corresponding active components were evaluated in an HCEC line with five in vitro assays. Cell proliferation and migration were measured using 3-(4,5)-dimethylthiahiazo (-z-y1)-3 5-di-phenytetrazolumromide (MTT) assay and transwell migration assay. Cell damage was determined with the lactate dehydrogenase (LDH) assay. Cell viability and median lethal time (LT₅₀) were measured by 7-amino-actinomycin D (7-AAD) staining and flow cytometry analysis.

Results: Cellular effects after exposure of HCECs to the four anti-inflammatory eye drops were concentration dependent. The differences of cellular toxicity on cell proliferation became significant at lower concentrations (<0.002%). Diclofenac Sodium Eye Drops showed significant increasing effects on cell damage and viability when compared with the other three solutions. Tobramycin & Dex Eye Drops inhibited the migration of HCECs significantly. Tobramycin & Dex Eye Drops showed the quickest effect on cell viability: the LT₅₀ was 3.28, 9.23, 10.38, and 23.80 min for Tobramycin & Dex Eye Drops, Diclofenac Sodium Eye Drops, Pranoprofen Eye Drops, and Bromfenac Sodium Hydrate Eye Drops, respectively. However, the comparisons of cellular toxicity revealed significant differences between the eye drops and their active components under the same concentration. The corneal epithelial toxicity differences among the active components of the four eye drops became significant as higher concentration (>0.020%).

Conclusions: The four anti-inflammatory eye drops showed different cellular effects on HCECs, and the toxicity was not related with their active components, which provides new reference for the clinical application and drug research and development.

Anti-inflammatory agents have been widely used systemically and topically in the treatment of ocular inflammatory conditions following cataract surgery and glaucoma surgery [1]. Ophthalmic corticosteroids have been the first-line therapy to reduce the postoperative inflammation by inhibition of phospholipase A₂ production. However, topical corticosteroid application may lead to impaired corneal wound healing, cataract formation, glaucoma by elevated intraocular pressure (IOP), and increased risk of infection [2]. Non-steroidal anti-inflammatory drugs (NSAIDs) exert an equivalent anti-inflammatory effect by inhibiting cyclooxgenases (COXs) that mediate the breakdown of arachidonic acid to produce prostaglandins and other metabolic products in the arachidonic acid cascade, and diclofenac sodium can also interfere with the lipoxygenase pathway [3]. Moreover, these drugs have shown an increasing use in managing posttraumatic or postoperative pain because of their analgesic effects, and they treat allergic ocular disorders by inhibiting prostaglandin synthesis [4,5]. Compared with corticosteroids, NSAIDs have become widely accepted to control ocular inflammation and pain because they do not raise IOP and they reduce the risk of secondary cataracts or infections [6].

Although the complications of NSAIDs are considerably less frequent than those of corticosteroids, some reports describe the adverse effects from topical NSAIDs, especially on conditions such as autoimmune disease or dry eyes. The most commonly reported adverse effects from topical NSAIDs include stinging, irritation, superficial punctate keratitis, corneal infiltrates, and melting [7]. In addition, NSAIDs inhibit COX activity in the arachidonic acid cascade and decrease prostaglandin synthesis. Prostaglandins are essential for protein and DNA synthesis in the epidermal cells; therefore, postoperative use of NSAIDs (especially diclofenac sodium) may affect corneal epithelial wound healing [3,8]. As reported previously, diclofenac sodium significantly delays early wound healing in the scraped rabbit corneal epithelium and re-epithelialization after penetrating keratoplasty [8].

Although a few articles have compared the effects of these anti-inflammatory eye drops on the proliferation or migration of corneal epithelial cells or conjunctival epithelial

Correspondence to: Associate Professor Qingjun Zhou, Shandong Eye Institute, 5 Yan’erdao Road, Qingdao, 266071, China; Phone: 86-532-8589-9270; FAX: 86-532-8589-1110; email: qjzhou2000@hotmail.com
Table 1. Anti-inflammatory eye drops used in the present study.

| Generic name                                     | Active component                | Preservative     | pH          |
|--------------------------------------------------|---------------------------------|------------------|-------------|
| Bromfenac Sodium Hydrate Eye Drops (Senju, Japan) | Bromfenac sodium hydrate (0.1%) | 0.005% BAC*      | 7.5–8.5     |
| Pranoprofen Eye Drops (Senju, Japan)              | Pranoprofen (0.1%)              | 0.007% BAC*      | 7.5–8.5     |
| Diclofenac Sodium Eye Drops (Sinji, China)        | Diclofenac sodium (0.1%)        | NK†              | 7.0–8.5     |
| Tobramycin & Dex Eye Drops (Alcon, USA)           | Tobramycin (0.3%) & Dex (0.1%)  | 0.001% BAC*      | 5.3‡        |

*BAC: Benzalkonium chloride; †NK: not known; ‡: measured result.

cells [9], little is known about the acute or early corneal cytotoxicity and the toxicity of their active components. In the present study, we systemically compared the cellular effects of three NSAIDs (Bromfenac Sodium Hydrate Eye Drops, Pranoprofen Eye Drops, and Diclofenac Sodium Eye Drops) and one corticosteroid solution (Tobramycin & Dex Eye Drops) and their corresponding active components on immortalized human corneal epithelial cells (HCECs) by using five in vitro assays, including 5-(4,5)-dimethylthiahiazolo-(z-y1)-3 5-di-phenytetrazoliumromide (MTT) assay, transwell migration assay, lactate dehydrogenase (LDH) assay, 7-amino-actinomycin D (7-AAD) staining and flow cytometry analysis. We found that the four anti-inflammatory eye drops showed different cellular effects on HCECs, and the toxicity was not related with their active components, which provides new reference for the clinical application and drug research and development.

METHODS

Eye drops: Senju Pharmaceutical Co., Ltd. (Osaka, Japan) provided the four anti-inflammatory eye drops and their active components for this study, including three NSAIDs (Bromfenac Sodium Hydrate Eye Drops, Pranoprofen Eye Drops, and Diclofenac Sodium Eye Drops) and one corticosteroid (Tobramycin & Dex Eye Drops). The active components of the four eye drops were dissolved in DMEM/F-12 (Invitrogen, Carlsbad, CA) media as the same concentration as that of the commercial solutions. Table 1 lists the main information of the four anti-inflammatory eye drops.

Human corneal epithelial cell culture: Simian virus 40–immortalized HCECs were provided by Choun-Ki Joo (The Catholic University of Korea, School of Medicine, Seoul, Korea). The cells were cultured in DMEM/F-12 (1:1) media, 5% fetal bovine serum (FBS; Gibco-BRL, Grand Island, NY), 5 μg/ml insulin (Sigma, St. Louis, MO), 0.1 ng/ml cholera toxin (EMD Biosciences, San Diego, CA), 10 ng/ml human epidermal growth factor (hEGF; R&D Systems, Minneapolis, MN), and 0.5% dimethyl sulfoxide (DMSO; Sigma) in a humidified 5% CO₂ incubator at 37 °C [10].

Cell proliferation assay: Cell proliferation was measured using MTT assay. Briefly, HCECs were inoculated 3,000 cells per well in 96-well plates and allowed to adhere. The media were aspirated and replaced with the media containing drugs with different dilutions for 24 h, followed by 4-h incubation with MTT. The MTT transformed crystals were dissolved in DMSO, and absorbance at 490 nm was measured using a microplate reader (SpectraMax M2, Molecular Devices, Menlo Park, CA).

Cell migration assay: Migration assay was performed on a 6.5-mm-diameter transwell chamber with an 8-μm pore size (Corning Costar, Cambridge, MA). HCECs (5×10⁴ cells) in the serum-free DMEM/F-12 media were inoculated on the top of the transwell chamber and allowed to migrate toward DMEM/F-12 medium containing 1% FBS supplemented with different drugs. Following 15 h incubation, the cells on the upper surface of the membranes were removed with cotton swabs, and the cells at the bottom of the filter were fixed with 100% ethanol for 10 min and stained with 0.1% crystal violet solution for 30 min. The dye was eluted using 33% acetic acid, and crystal violet absorbance was measured at 570 nm using the microplate reader.

Cell damage measurement: Early cell damage was determined using the LDH cytotoxicity detection kit (Promega, Madison, WI), which quantifies the LDH release from the cells into the culture medium. The HCECs were seeded 5,000 cells per well in 96-well plates for 24 h to promote adherence. The cells were treated as the same as the evaluation of cell proliferation. Cell-free supernatants from the cultures were collected, passed through a 0.2-μm filter, and used in the LDH assay as instructed by the manufacturer. Maximum LDH release (high control) was determined by solubilizing cells with 1% Triton X-100, and spontaneous LDH release (low control) was determined by incubating cells with the medium alone. A reduction reaction of tetrazolium salt (INT) to a red formazan salt was used as an indicator of LDH activity in the supernatant. Absorbance was read at 490 nm by using a microplate reader. Results were quantified as (experimental value - low control/high control - low control) × 100.

Cell viability detection: HCECs were seeded for 24 h and then incubated with different drugs for another 24 h. Next, the cells were collected by centrifugation and incubated by 7-AAD staining (1 μg/ml final concentration; 7-AAD; BD PharMingen, San Diego, CA). Cell mortality rate was measured using flow cytometry.

Median lethal time assay: HCECs (3×10⁵ cells) were collected and treated with 100-μl undiluted anti-inflammatory eye
drops for different exposure times. The treatment was stopped by 10-ml DMEM/F-12 media containing 10% FBS. The cells were then labeled by 7-AAD staining, and the cell viability was measured using flow cytometry. Median lethal time (LT$_{50}$, time when the mortality rate was 50%) was counted according to the cell viability curve.

Figure 1. Effects of the four anti-inflammatory eye drops on the proliferation of cultured HCECs. HCECs were treated with 0.001%, 0.002%, and 0.010% eye drops for 24 h (n=4) and analyzed by morphological observation (A) and MTT assay (B). The inhibitory effects of the four eye drops were in a concentration-dependent manner, and the differences among the four solutions became less significant as the concentrations increased. All the experiment groups showed a significant inhibitory effect when compared with the control except for the Pranopronfen Eye Drops and Bromfenac Sodium Hydrate Eye Drops at the 0.001% concentration.
Figure 2. Influence of the four anti-inflammatory eye drops on the migration of cultured HCECs. HCECs were inoculated on the top of the transwell chamber and were induced to migrate toward the lower chambers containing the 0.001% eye drops and 1% FBS for 15 h (n=4). The transmigrated HCECs were stained with crystal violet and visualized with a microscope (A). The dye was eluted with acetic acid, and the crystal violet absorbance was measured (B). Only Tobramycin & Dex Eye Drops showed a significant difference compared with the control at the concentration.

Statistical analysis: Data are presented as mean±SD. The differences were analyzed by SPSS 10.0 (SPSS Inc., Chicago, IL) software (one-way ANOVA) with a significance value of p<0.05.
RESULTS

Comparisons of corneal epithelial effects among anti-inflammatory eye drops: To evaluate the cellular effects of the four anti-inflammatory eye drops on HCECs, five assays were used in the present study. Acute cytotoxicity was evaluated by the measurement of median lethal time, chronic cellular effects were evaluated by the cell proliferation, migration, damage, and cell viability assay, in which corneal epithelial cells were treated with individual eye drops for 15 or 24 h.

The effects on the proliferation of cultured HCECs were evaluated with MTT assay. HCECs were incubated with 0.001% (10 fold dilution), 0.002% (50 fold dilution), and 0.010% (10-fold dilution) eye drops for 24 h. The proliferation inhibition of the four eye drops was in a concentration-dependent manner, and the differences among the four solutions became less significant as the concentrations increased. All the experiment groups showed a significant inhibitory effect when compared with the control except for the Pranoprofen Eye Drops and Bromfenac Sodium Hydrate Eye Drops at the 0.001% concentration; there were no differences between these two groups (Figure 1A,B).

Cell migration plays an important role in corneal wound healing. We used the transwell migration assay to quantify the effects of eye drops (0.001%) on the migration of cultured HCECs. The transmigrated cells were stained with crystal violet (Figure 2A) and the absorbance of elution was measured. There was no significant influence on HCEC migration compared with the control, except for Tobramycin & Dex Eye Drops (Figure 2B).
Cellular toxicity always causes membrane damage and results in the releasing of LDH from the cytoplasma. By detecting the LDH in cell supernatant with 0.001%, 0.002%, and 0.010% eye drops, we found that Diclofenac Sodium Eye Drops showed the most significant toxicity among the four solutions at three concentration groups. At the higher 0.010% concentration, all four solutions caused apparent cell damage, LDH releasing, and the differences among them became less significant (Figure 3). The results were basically identical with the measurement of cell mortality by 7-AAD staining at the 0.001% concentration (Figure 4). The number of dead cells treated with Diclofenac Sodium Eye Drops showed almost 3–5 folds of the cells treated with the other three solutions.

Acute cytotoxicity was detected by treating the HCECs with the original eye drops. The LT50 of the four anti-inflammatory eye drops was 23.80 min for Bromfenac Sodium Hydrate Eye Drops, 10.38 min for Pranoprofen Eye Drops, 9.23 min for Diclofenac Sodium Eye Drops, and 3.28 min for Tobramycin & Dex Eye Drops (Figure 5), indicating that Tobramycin & Dex Eye Drops had the fastest toxicity effect, followed by Diclofenac Sodium Eye Drops, Pranoprofen Eye Drops, and Bromfenac Sodium Hydrate Eye Drops.

According to cell proliferation, damage, and cell viability assay, Bromfenac Sodium Hydrate Eye Drops had the least significant corneal epithelial effects whereas Diclofenac Sodium Eye Drops had the most significant corneal epithelial effects among the four anti-inflammatory eye drops. Tobramycin & Dex Eye Drops showed the most significant influence on cell migration and acute cytotoxicity.

**Comparison of corneal epithelial effects among the active components of anti-inflammatory eye drops:** MTT and LDH assays were used to evaluate the cytotoxicity of the active components of the four eye drops. The results indicated that Diclofenac Sodium Eye Drops (contains 0.1% diclofenac sodium) showed significant toxicity on the proliferation and damage of HCECs when compared with the control and the active components. The cellular toxicity of the four anti-inflammatory eye drops did not originate from the active components but from the preservatives or other ingredients.

**DISCUSSION**

Ocular epithelial disorders after eye surgery can result in visual deterioration and patient discomfort, which may be caused by drug toxicity. In the present study, we systematically evaluated the overall cellular effects of four commercially available anti-inflammatory eye drops and their active components on HCECs in vitro. The results indicated that Diclofenac Sodium Eye Drops showed significant effects on cell damage and viability, which was consistent with previous reports [7,11, 12]. The cytotoxicity of diclofenac was represented by retarding corneal epithelial healing [8,13], decreasing cell growth [14], and causing the higher incidence of persistent epithelial defects [15]. The mechanism related with diclofenac not only blocks the COX pathway but also diminishes the pool...
of available arachidonic acid. Arachidonic acid is an important component of cellular structural integrity; the lack of its availability and the potentially increased permeability of cellular membranes may lead to corneal epithelial cell death and keratolysis [16,17]. It should be mentioned that Tobramycin & Dex Eye Drops inhibited the migration and showed the quickest effect on cell viability in the study. However, the inhibitory effect on corneal epithelial migration was related with Dex, and the inhibition of cell viability was caused by the presence of Tobramycin, according to our previous study (data not shown).

It should be mentioned that there were significant differences between acute and chronic cellular effects among these four anti-inflammatory eye drops. As previous description, steroid levels in the cornea decrease by 50% within 1 h after topical application [18], while the aqueous humor concentrations of topically applied Diclofenac and Bromfenac gradually decreased until complete removal after approximately 24 h because of the rapid turnover of tear, aqueous humor, etc. [19,20]. However, the concentrations of eye drops exposed to human corneal epithelial cells in vitro remained constant, which represents the early higher concentrations when topical application in vivo. For these reasons, the 24 h exposure of cultured epithelial cells to eye drops in the present study was parallel with the long-term exposure time and concentration experienced by epithelial cells in vivo. Moreover, the HCECs showed significant toxicity when exposed to the constant concentrations of eye drops of the active components of the four anti-inflammatory eye drops on cultured HCECs. HCECs were treated with 0.010%, 0.020%, 0.050%, and 0.100% solutions for 24 h (n=4) and analyzed by MTT assay (A) and LDH assay (B). Only diclofenac and bromfenac components showed significant cytotoxicity at the concentrations above 0.020% and 0.100%.
drops in vitro, so we measured the acute cellular toxicity within 1 h, while measured the chronic cellular toxicity within 24 h. More importantly, we first found significant differences between the eye drops and their active components under the 0.010% concentration, but we did not find any differences among their active components at the same concentrations. Moreover, the pH values of 0.001%, 0.002%, and 0.010% eye drops diluted in cell culture media became almost identical (data not shown). The above results suggest that the corneal epithelial toxicity of the four anti-inflammatory eye drops were independent in their active components or pH values, especially in the lower concentrations (<0.010%).

As reported previously, preservatives and buffering agents are essential ingredients except of active components in eye drops. They provide a level of antimicrobial activity and prolong the half-life of the drug by preventing biodegradation and maintaining drug potency [21]. However, long-term topical use may cause tear film instability, loss of goblet cells, ocular epithelial squamous metaplasia and apoptosis, disruption of corneal epithelium barrier, and

Figure 7. Comparisons of corneal epithelial toxicity of anti-inflammatory eye drops and their active components. HCECs were treated with either 0.010% eye drops or 0.010% active components for 24 h (n=4). The corneal epithelial toxicity was measured by MTT assay (A) and LDH assay (B). Significant differences were between the eye drops and the corresponding active components.
damage to deeper ocular tissues. Therefore, care should be taken to avoid long-term use of preservative-containing eye drops or to use preservative-free solutions whenever possible. Diclofenac sodium eye drops containing thimerosal from Japan or Europe caused punctuating corneal epithelial damage, whereas the USA products containing sorbic acid or the diclofenac sodium solution alone had no significant toxicity. Because the present study had limited product information about the components, contents, and possible interactions between the preservatives and other agents, it is necessary to further investigate the origin of cellular toxicity.

ACKNOWLEDGMENTS

The work was supported by Senju Pharmaceutical Co., Ltd. We also thank for Dr. Xianggen Wu’s helpful discussion.

REFERENCES

1. McCollgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2000; 11:3-6. [PMID: 10724825]
2. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002; 25:33-55. [PMID: 11820911]
3. Lindstrom R. The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. Int Ophthalmol Clin 2006; 46:7-11. [PMID: 17060787]
4. Kapin MA, Yanni JM, Brady MT, McDonough TJ, Flanaqan LJ, Foster CS. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmal 1990; 108:577-83. [PMID: 2322160]
5. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000; 24:357-70. [PMID: 10850857]
6. Assouline M, Renard G, Arne JL, David T, Lasmolles C, Maleczae F, Pouliken YJ. A prospective randomized trial of topical soluble 0.1% indomethacin versus 0.1% diclofenac versus placebo for the control of pain following excimer laser photorefractive keratectomy. Ophthalmic Surg Lasers 1998; 29:365-74. [PMID: 9599360]
7. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001; 108:936-44. [PMID: 11320025]
8. Hersh PS, Rice BA, Baer JC, Wells PA, Lynch SE, McGuiqan LJ. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmal 1990; 108:577-83. [PMID: 2322160]
9. Ayaki M, Iwasawa A, Soda M, Yaguchi S, Koide R. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clin Ophthalmol 2010; 4:1019-24. [PMID: 20922036]
10. Kim SY, Lim JA, Choi JS, Choi EC, Joo CK. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 2007; 26:720-5. [PMID: 17592324]
11. O’Brien TP, Li QJ, Sauerburger F, Reviglio VE, Rana T, Ashraf MF. The role of matrix metalloproteinases in ulcerative keratitis associated with perioperative diclofenac use. Ophthalmology 2001; 108:656-9. [PMID: 11297478]
12. Hsu JK, Johnston WT, Read RW, McDonnell PJ, Panqalinan R, Rao N, Smith RE. Histopathology of corneal melting associated with diclofenac use after refractive surgery. J Cataract Refract Surg 2003; 29:250-6. [PMID: 12648633]
13. Tomas-Barberan S, Fagerholm P. Influence of topical treatment on epithelial wound healing and pain in the early postoperative period following photorefractive keratectomy. Acta Ophthalmol Scand 1999; 77:135-8. [PMID: 10321525]
14. Takahashi N, Miyakoshi M, Taka N, Kurihara T, Fujikawa K. Cytotoxic effects of diclofenac sodium. Nippon Ganka Gakkai Zasshi 1993; 97:145-9. [PMID: 8475823]
15. Shimazaki J, Saito H, Yang HY, Toda I, Fujishima H, Tsubota K. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eye drops. Cornea 1995; 14:263-7. [PMID: 8575187]
16. Ku EC, Lee W, Kothari HV, Scholer DW. Effects of diclofenac sodium on the arachidon acid cascade. Am J Med 1986; 80:18-23. [PMID: 3085488]
17. Ueymura SA, Santos AC, Mingatto FE, Jordani MC, Curti C. Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch Biochem Biophys 1997; 342:231-5. [PMID: 9186483]
18. Short C, Keates RH, Donovan EF, Wyman M, Murdick PW. Ocular penetration studies. I. Topical administration of Dex. Arch Ophthalmol 1966; 75:689-92. [PMID: 5936375]
19. Ellis PP, Pfoff DS, Bloedow DC, Riegel M. Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. J Ocul Pharmacol 1994; 10:677-82. [PMID: 7714411]
20. Isaka M, Inada K, Tsutsumi S, Fushimi M, Inaba A, Karasawa JG, Rawji MH, Dahlin DC, Sanders ME, Gamache DA. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clin Ophthalmol 2010; 4:1019-24. [PMID: 20922036]